arrow
D

Daniela Cilloni

University of Turin
H指数:47
被引数:9,122

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib

鲁索利替尼治疗患者的真性红细胞增多症长期结局动态预测模型

2026-06-150
OAAI
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists

GIMEMA关于慢性髓性白血病患者在第三线及以后治疗管理情况的调查:来自意大利血液学家的见解

2025-11-180
OAAI
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

接受维奈克拉联合表观遗传药物治疗的患者的生存情况受治疗前合并症负担的影响

2025-01-200
OAAI
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
CANCER
IF5.1
2023-12-284
OAAI
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

Olutasidenib (FT-2102) 可诱导复发或难治性IDH1-mutated AML患者持久完全缓解

2023-06-3048
OAAI
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

luspatercept的真实世界疗效和安全性以及对具有环状成纤维细胞的低风险骨髓增生异常综合征患者的反应预测因素

2023-05-246
OAAI
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

异基因造血干细胞移植与omiudubicel的多中心长期随访: 五项前瞻性临床试验的汇总分析

2023-05-017
OAAI
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
CANCER
IF5.1
2023-03-1821
OAAI
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
2022-01-1141
OAAI